NYSE:NVO - Novo Nordisk A/S Stock Price, Forecast & News

Novo Nordisk A/S trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVO."

Novo Nordisk A/S declared a Semi-Annual dividend on Friday, August 9th. Investors of record on Monday, August 19th will be paid a dividend of $0.318 per share on Tuesday, August 27th. The ex-dividend date is Friday, August 16th. View Novo Nordisk A/S's Dividend History.

Novo Nordisk A/S declared that its board has authorized a share repurchase plan on Friday, February 2nd 2018, which allows the company to repurchase outstanding shares, according to EventVestor. This repurchase authorization allows the company to repurchase shares of its stock through open market purchases. Shares repurchase plans are often a sign that the company's board believes its shares are undervalued.

Novo Nordisk A/S (NYSE:NVO) posted its earnings results on Friday, November, 1st. The company reported $0.64 EPS for the quarter, topping analysts' consensus estimates of $0.62 by $0.02. The firm earned $4.51 billion during the quarter, compared to analysts' expectations of $4.55 billion. Novo Nordisk A/S had a net margin of 32.44% and a return on equity of 75.48%. View Novo Nordisk A/S's Earnings History.

Novo Nordisk A/S is scheduled to release their next quarterly earnings announcement on Friday, February 7th 2020. View Earnings Estimates for Novo Nordisk A/S.

12 equities research analysts have issued 1 year target prices for Novo Nordisk A/S's shares. Their forecasts range from $48.61 to $400.00. On average, they anticipate Novo Nordisk A/S's share price to reach $181.58 in the next twelve months. This suggests a possible upside of 195.7% from the stock's current price. View Analyst Price Targets for Novo Nordisk A/S.

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novo Nordisk A/S in the last year. There are currently 1 sell rating, 7 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Novo Nordisk A/S.

Media headlines about NVO stock have been trending negative recently, according to InfoTrie. The research firm scores the sentiment of media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Novo Nordisk A/S earned a media sentiment score of -2.3 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the near future. View News Stories for Novo Nordisk A/S.

Some companies that are related to Novo Nordisk A/S include Johnson & Johnson (JNJ), Roche Holdings AG Basel (RHHBY), Merck & Co., Inc. (MRK), Pfizer (PFE), Novartis (NVS), Abbott Laboratories (ABT), Eli Lilly And Co (LLY), AstraZeneca (AZN), AbbVie (ABBV), Sanofi (SNY), GlaxoSmithKline (GSK), Bristol-Myers Squibb (BMY), Commonwealth Bank of Australia (CSLLY), Bayer (BAYRY) and Celgene (CELG).

Based on aggregate information from My MarketBeat watchlists, some companies that other Novo Nordisk A/S investors own include Gilead Sciences (GILD), AbbVie (ABBV), Pfizer (PFE), QUALCOMM (QCOM), Johnson & Johnson (JNJ), AT&T (T), NVIDIA (NVDA), Starbucks (SBUX), Cisco Systems (CSCO) and Alibaba Group (BABA).

Novo Nordisk A/S's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Scout Investments Inc. (0.01%), Janney Montgomery Scott LLC (0.00%), Atwater Malick LLC (0.00%), Commerzbank Aktiengesellschaft FI (0.00%), Smithbridge Asset Management Inc. DE (0.00%) and OmniStar Financial Group Inc. (0.00%). View Institutional Ownership Trends for Novo Nordisk A/S.

NVO stock was sold by a variety of institutional investors in the last quarter, including Loring Wolcott & Coolidge Fiduciary Advisors LLP MA, Commerzbank Aktiengesellschaft FI, First Hawaiian Bank, Scout Investments Inc., Norris Perne & French LLP MI, Smithbridge Asset Management Inc. DE, Norman Fields Gottscho Capital Management LLC and OmniStar Financial Group Inc.. View Insider Buying and Selling for Novo Nordisk A/S.

NVO stock was acquired by a variety of institutional investors in the last quarter, including Chemung Canal Trust Co., Janney Montgomery Scott LLC, We Are One Seven LLC, Calamos Advisors LLC, Ingalls & Snyder LLC, SeaCrest Wealth Management LLC, Atwater Malick LLC and Huntington National Bank. View Insider Buying and Selling for Novo Nordisk A/S.

Shares of NVO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of NVO stock can currently be purchased for approximately $61.40.

Novo Nordisk A/S has a market capitalization of $145.40 billion and generates $17.72 billion in revenue each year. The company earns $5.91 billion in net income (profit) each year or $2.52 on an earnings per share basis. Novo Nordisk A/S employs 43,202 workers across the globe.View Additional Information About Novo Nordisk A/S.

The official website for Novo Nordisk A/S is http://www.novonordisk.com/.

Novo Nordisk A/S's mailing address is Novo Alle, Bagsvaerd G7, 2880. The company can be reached via phone at 45-4444-8888 or via email at [email protected]